Peg-Intron Articles

Schering-Plough’s income dips in 3rd quarter 2009, hit by charges

23 October 2009

Locteron shows better AE profile than PEG-Intron

24 April 2009

S-P's boceprevir reduces SVR after 28 weeks in Ph II study

24 April 2009

FDA expands indication for S-P hep C combo

30 March 2009

Schering-Plough finally back in profit after Organon buy; exceeds expectations, pleasing shareholders

9 February 2009

S-P's Pegintron/Rebetol approved in children

22 December 2008

S-P claims superior pipeline to competitors; new drugs could make $7B in next 4 years

8 December 2008

"Unprecedented" 75% SVR24 for boceprevir

1 December 2008

S-P's boceprevir doubles SVR24 in Ph II study

10 November 2008

Pegasys/Copegus effective in non-responders

10 November 2008

S-P profit falls 21%, still up on predictions

27 October 2008

China hep C market to grow to $150M in 2012

15 September 2008

China's hep B market $800M by 2012

8 September 2008

S-P's boceprevir shows 74% SVR in HCV

11 August 2008

EU's pediatric drug c'tee celebrates first birthday

28 July 2008

S-P profit down again on Organon charges

28 July 2008

Roche's Pegasys fares well vs peg-IFN alfa-2b

5 May 2008

S-P's boceprevir sees 57% SVR at 28 weeks

5 May 2008

Similar SVRs for S-P and Roche HCV combos

5 May 2008

UPDATE: S-P profit down, sales up on Organon buy

5 May 2008

OctoPlus' Locteron impresses in Ph I study

17 March 2008

S-P's 4th-qtr 2007 results hit by Organon buy

18 February 2008

OctoPlus begins dosing in US Locteron study

11 February 2008

Further EU approval for S-P's HCV drug combo

26 November 2007

Pegintron plus Rebetol achieves consistent SVR

21 November 2007

S-P's boceprevir boosts HCV clearance rates

29 October 2007

S-P's 3rd-qtr 2007 net income surges 149%

29 October 2007

CHMP recommends S-P's HCV drug regimen

1 October 2007

Drug Royalty buys 25% of Peg-Intron royalties

3 September 2007

S-P's 2nd-quarter 2007 EPS doubles to $0.34

30 July 2007

S-P's Pegintron plus Rebetol gets expanded indication

9 July 2007

S-P's Pegintron combo therapy gets tentative EU approval

7 May 2007

Schering-Plough 1st-qtr profits leap 55%

30 April 2007

S-P's Pegintron cleared in China for HBV

16 April 2007

Schering-Plough delivering on Action Agenda, with 4th-qtr profits up 62%

5 February 2007

S-P announces its AASLD presentation program

6 November 2006

S-P's 3rd-qtr 2006 net income improves

30 October 2006

UK OKs combination hepatitis C treatments

4 September 2006

Schering-Plough sees 2nd-qtr income of $237.0M as sales rise 11% to $2.8 billion

31 July 2006

An overview of European Association for the Study of Liver 41st annual meeting

22 May 2006

S-P starts recovery: 1st-qtr 2006 profit up 233%

1 May 2006

S-P completes enrollment in first stage of Ph II trial of HCV drug

24 April 2006

Review of 2nd International Workshop on HIV and Hepatitis Co-infection

13 February 2006

Schering-Plough's turnaround continues with 4th-qtr earnings at $104M

6 February 2006

New indications in Japan for S-P drugs

9 January 2006

NZ Pharmac gets budget boost, OKs new Rx uses

8 August 2005

Shorter dosing recommendations for S-P's PEG-Intron and Rebetol by CHMP

8 August 2005

Litigation reserves bite into Schering-Plough's 2nd-qtr, but sales rise 18%

1 August 2005

Schering-Plough expands in Asia Pacific

18 July 2005

PegIntron/ribavirin 12-week therapy effective

4 July 2005

Israel's 2005 NHI drugs basket creates precedents for funding and registration

16 May 2005

Clarification:

28 April 2005

PegIntron/Rebetol in HCV: positive data

25 April 2005

Schering-Plough back in profit for 1st-qtr

22 April 2005

Schering-Plough aims for 100B yen sales in Japan by 2010

18 April 2005

Schering-Plough beats analysts' expectations seeing a turnaround in 4th-qtr 2004

31 January 2005

Lack of effective treatments for chronic hep B and C, markets driven by cost: study

24 January 2005

New data show S-P's PegIntron to be an effective monotherapy for hepatitis B

17 January 2005

S-P's Peg-Intron launched in Japan

20 December 2004

Promising new results for Roche's Pegasys confirm its efficacy for hepatitis C

8 November 2004

Schering-Plough's Peg-Intron OKed in Japan

1 November 2004

Hep C patients benefit from shorter course of Schering-Plough's PegIntron

7 June 2004

S-P posts 1st-qtr loss of $73M as sales slide

3 May 2004

Schering-Plough cutting jobs in Ireland

19 January 2004

EU changes label for S-P's PegIntron

27 October 2003

S-P to compare hep C therapies

6 October 2003

New data show PegIntron should be given twice-weekly

4 August 2003

Roche's Pegasys shows promise as a therapy for hepatitis B virus infections

14 July 2003

S-P, Novartis link up on asthma product

21 April 2003

NPS Pharma and Enzon to merge in $1.6B deal; aim to be "a new biotech leader"

3 March 2003

Roche undercuts rival with ribavirin brand

20 January 2003

Ribapharm sues Roche for patent infringement

12 August 2002

FDA grants Pegasys fast-track review

22 July 2002

Schering-Plough announces flat EPS for 2nd-qtr, re-emphasizes depth of pipeline

22 July 2002

Ribapharm confident on 2nd-qtr results

15 July 2002

Global hepatitis market "set to reach $3.97 billion by 2007"

1 July 2002

Roche gets OKs for Pegasys, Copegus

1 July 2002

Ribapharm reports 107% rise in first-quarter royalty revenues

13 May 2002

Roche pipeline set to deliver renewed momentum after 2004

6 May 2002

Roche's Pegasys: "unprecedented efficacy in hep C"

29 April 2002

ICN defending ribavirin patent

11 March 2002

Record revenues reported at ICN

4 March 2002

New NICE appraisal program goes for one-month consultation

25 February 2002

Enzon starts Phase II study in lung cancer

18 February 2002

Analyst considers impact that loss of US Accutane patent will have on Roche

4 February 2002

S-P's PEG-Intron demand difficulties.

21 January 2002

ICN earnings to exceed expectations.

21 January 2002

Maxim initiates Ceplene Phase II trials

7 January 2002

Maxim initiates Ceplene Phase II trials

19 December 2001

Roche and Chugai enter alliance with the Swiss firm the majority shareholder

10 December 2001

S-P's PEG-Intron/ribavirin combo works in relapses

15 November 2001

Maxim to initiate Ph II Ceplene trials

8 November 2001

Sales flat at Schering-Plough as manufacturing problems persist

23 October 2001

Enzon goes into profit in 4th qtr

22 August 2001

Roche posts strong-than-expected results as pharma sales pick up

16 August 2001

Roche, S-P resolve peginterferon dispute

13 August 2001

US approval for S-P's Peg-Intron in combo with Rebetol for hep C

9 August 2001

ICN Pharma earnings take a downturn

3 August 2001

FDA approves Rebetol as separate treatment

31 July 2001

Flat 2nd-qtr sales/EPS at Schering-Plough

25 July 2001

Showing 1-100 of 127 articles

Go to beginningPreviousNextGo to end